Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2002 Aug;3(8):1196-8.Links

ART-123 Asahi Kasei.

Khorchidi S, Bantleon R, Kehlbach R, Tepe G, Wiskirchen J, Duda SH.

Department of Radiology, University of Tübingen, Germany. sascha.khorchidi@uni-tuebingen.de

Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism [169907]. By September 2000, it had entered phase III trials [383525]. A patent, US-05916874, claiming a method for treating liver injury and whose composition comprises a thrombomodulin, was published in 1999 by the company.

PMID: 12211414 [PubMed - indexed for MEDLINE]

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on